Skip to main content
. 2021 Jun 11;12:631603. doi: 10.3389/fimmu.2021.631603

Figure 2.

Figure 2

Association of the IL-33 rs16924159 polymorphism with disease activity in rheumatoid arthritis patients. (A) Comparison of IL-33 rs16924159 genotype frequencies with DAS28 score at baseline as well as at 12th and 24th weeks after commencing of anti-TNF therapy; (B) Comparison of IL-33 rs16924159 genotype frequencies with relative change in DAS28 between baseline and 12th week, as well as 24th week after commencing of anti-TNF therapy; Differences are indicated as; αAA vs AG+GG, p=0.023, p c=NS, OR= 1.97, CI95%=(1.06; 3.67); βGG vs AA, p=0.049, p c=NS, OR=0.51, CI95%=(0.25; 1.00); γAA vs GG, p=0.036, p c=NS, W=2396.5; δAA vs AG+GG, p=0.030, p c=NS, W=5265.5; ϵGG vs AA, p=0.016, p c=NS, W=2301.0; DAS28, disease activity score 28; NS, non-significant; p c, value with Bonferroni correction.